MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 04-28-2026
OPKO Health Net Debt 2011-2026 | OPK
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt OPKO Health
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -411 M | -75.2 M | -132 M | 82.2 M | 163 M | 184 M | 108 M | 55.3 M | -73.5 M | -58.1 M | 50.4 M | 41.9 M | -4.68 M | -62.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 184 M | -411 M | -9.48 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B |  USA |
 |
Fulgent Genetics
FLGT
|
-53.3 M | $ 17.5 | 2.25 % | $ 539 M | USA |
 |
Guardant Health
GH
|
1.15 B | $ 119.01 | 0.05 % | $ 14.9 B | USA |
 |
Interpace Biosciences
IDXG
|
-1.32 M | $ 1.8 | -1.1 % | $ 7.96 M | USA |
 |
Agilent Technologies
A
|
1.24 B | $ 114.58 | -0.33 % | $ 34.8 B | USA |
 |
Celcuity
CELC
|
-28.1 M | $ 135.07 | -2.29 % | $ 6.32 B | USA |
 |
Illumina
ILMN
|
-494 M | $ 145.77 | 0.94 % | $ 23.2 B | USA |
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
-10.6 M | $ 8.22 | 62.13 % | $ 10.9 M | USA |
 |
Castle Biosciences
CSTL
|
-106 M | $ 19.83 | -1.59 % | $ 575 M | USA |
 |
Aspira Women's Health
AWH
|
-512 K | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-14.5 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M |  Britain |
 |
CareDx, Inc
CDNA
|
-39.2 M | $ 21.72 | 0.42 % | $ 1.16 B | USA |
 |
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-3.13 M | - | - | $ 9.42 M |  Israel |
 |
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | USA |
 |
Lantheus Holdings
LNTH
|
213 M | $ 100.16 | -2.76 % | $ 6.76 B | USA |
 |
ICON Public Limited Company
ICLR
|
4.63 B | $ 114.39 | -2.05 % | $ 9.44 B |  Irlanda |
 |
Mettler-Toledo International
MTD
|
2.06 B | $ 1 097.99 | -0.46 % | $ 22.6 B |  Schweiz |
 |
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M |  China |
 |
NeoGenomics
NEO
|
187 M | $ 9.24 | 0.05 % | $ 1.18 B | USA |
 |
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-789 K | - | - | $ 7.1 B |  Australia |
 |
National Research Corporation
NRC
|
71.3 M | $ 18.87 | -1.1 % | $ 422 M | USA |
 |
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | China |
 |
Natera
NTRA
|
-177 M | $ 201.52 | -0.82 % | $ 19.8 B | USA |
 |
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | USA |
 |
Charles River Laboratories International
CRL
|
1.98 B | $ 156.44 | -2.41 % | $ 7.75 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | USA |
 |
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Medpace Holdings
MEDP
|
-360 M | $ 428.17 | -1.07 % | $ 12.4 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-916 M | - | - | $ 19.8 B | USA |
 |
Myriad Genetics
MYGN
|
-22.8 M | $ 3.75 | -1.96 % | $ 347 M | USA |
 |
Personalis
PSNL
|
-117 M | $ 9.07 | 7.09 % | $ 809 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
2.48 B | $ 26.87 | -0.3 % | $ 25.5 B |  Niderland |
 |
Senseonics Holdings
SENS
|
-4.15 M | $ 6.53 | 3.0 % | $ 272 M | USA |
 |
QIAGEN N.V.
QGEN
|
1.31 B | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
-19.5 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
-1.94 M | $ 2.44 | -1.81 % | $ 5.6 M | USA |
 |
Twist Bioscience Corporation
TWST
|
-107 M | $ 63.84 | 5.4 % | $ 3.82 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
4.74 B | $ 259.16 | -0.3 % | $ 21.6 B | USA |
 |
Thermo Fisher Scientific
TMO
|
29.6 B | $ 446.9 | -0.31 % | $ 168 B | USA |
 |
Trinity Biotech plc
TRIB
|
55.4 M | $ 0.62 | 3.02 % | $ 223 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
-3.55 M | - | -34.28 % | $ 263 K | Israel |
 |
Waters Corporation
WAT
|
391 M | $ 340.17 | -0.64 % | $ 20.3 B | USA |
 |
Neogen Corporation
NEOG
|
751 M | $ 8.93 | 0.34 % | $ 1.94 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
4.92 B | $ 193.1 | -1.08 % | $ 21.4 B | USA |